View in EDS HTML Full Text PDF Full Text

Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.

Saved in:
Bibliographic Details
Title: Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
Authors: Sindher SB; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Kumar D; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Cao S; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Purington N; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Quantitative Sciences Unit, Stanford University, Stanford, California, USA., Long A; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Sampath V; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA., Zedeck SS; University of California, Los Angeles, California, USA.; Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA., Woch MA; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA., Garcia-Lloret M; University of California, Los Angeles, California, USA.; Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA., Chinthrajah RS; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.
Source: Allergy [Allergy] 2022 Jun; Vol. 77 (6), pp. 1873-1884. Date of Electronic Publication: 2022 Jan 24.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1398-9995 (Electronic) Linking ISSN: 01054538 NLM ISO Abbreviation: Allergy Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35014049
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sindher+SB%22">Sindher SB</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Kumar+D%22">Kumar D</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Cao+S%22">Cao S</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Purington+N%22">Purington N</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Quantitative Sciences Unit, Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Long+A%22">Long A</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Sampath+V%22">Sampath V</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Zedeck+SS%22">Zedeck SS</searchLink>; University of California, Los Angeles, California, USA.; Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Woch+MA%22">Woch MA</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.<br /><searchLink fieldCode="AU" term="%22Garcia-Lloret+M%22">Garcia-Lloret M</searchLink>; University of California, Los Angeles, California, USA.; Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Chinthrajah+RS%22">Chinthrajah RS</searchLink>; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227804028%22">Allergy</searchLink> [Allergy] 2022 Jun; Vol. 77 (6), pp. 1873-1884. <i>Date of Electronic Publication: </i>2022 Jan 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>Denmark <i>NLM ID: </i>7804028 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1398-9995 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201054538%22">01054538 </searchLink><i>NLM ISO Abbreviation: </i>Allergy <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35014049
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/all.15217
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1873
    Titles:
      – TitleFull: Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sindher SB
      – PersonEntity:
          Name:
            NameFull: Kumar D
      – PersonEntity:
          Name:
            NameFull: Cao S
      – PersonEntity:
          Name:
            NameFull: Purington N
      – PersonEntity:
          Name:
            NameFull: Long A
      – PersonEntity:
          Name:
            NameFull: Sampath V
      – PersonEntity:
          Name:
            NameFull: Zedeck SS
      – PersonEntity:
          Name:
            NameFull: Woch MA
      – PersonEntity:
          Name:
            NameFull: Garcia-Lloret M
      – PersonEntity:
          Name:
            NameFull: Chinthrajah RS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2022 Jun
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1398-9995
          Numbering:
            – Type: volume
              Value: 77
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Allergy
              Type: main
ResultId 1